What You Should Know:– Flatiron Health, a leading technology company focused on improving cancer care announced a strategic partnership with Exact Sciences, a pioneer in cancer screening and diagnostics to accelerate clinical evidence generation for Exact Sciences’ molecular residual disease (MRD) test, Oncodetect™.– The collaboration will leverage Flatiron’s innovative clinical research platform and extensive network of community oncology practices to study the test’s performance in diverse patient populations and real-world settings.Leverage Real-World Data and Community Oncology Settings to Advance Cancer CareMRD testing is a rapidly evolving field in oncology, with the potential to transform cancer care by detecting residual disease after treatment and guiding personalized treatment decisions. However, generating robust clinical evidence for MRD tests can be challenging and time-consuming.This partnership aims to address this challenge by:Leveraging real-world data: Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting.Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting. Focusing on diverse patient populations: Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials.Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials. Accelerating evidence generation: Employing a novel prospective clinical evidence generation platform and pragmatic study design to expedite the research process.First Patient EnrolledThe partnership has already achieved a significant milestone with the enrollment of the first patient in the study in under six months from conception. This rapid progress highlights the strong collaboration and commitment to execution between Flatiron Health and Exact Sciences.“Our partnership with Exact Sciences leverages Flatiron’s next-generation prospective evidence platform, which we designed to address critical evidence gaps via studies embedded into routine care, with unprecedented speed,” said Alex Deyle, general manager, Clinical Research, Flatiron Health. “Our in-house team of experts, experienced site network, fit-for-purpose research operations, and cutting-edge technology that focuses on reducing site burden, has enabled us to run more efficient and representative prospective studies.”

Willowglade, Flatiron Health Partner to Enhance the Oncology Patient Experience. by Syed Hamza Sohail 11/22/2024 Leave a Comment. What You Should Know:– Willowglade Technologies®, provider of the only Unified Digital Patient Experience™ Platform available to oncology practices nationwide, announced a new partnership with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology.– The partnership aims to enhance patient centered care by expanding the availability of the Unified Digital Patient Experience™ Platform to practices using Flatiron’s OncoEMR®, a leading cloud based electronic medical record.Transforming Oncology Care: Willowglade and Flatiron’s Unified Digital Patient ExperienceTM Platform The Unified Digital Patient ExperienceTM Platform by Willowglade represents a transformative advancement in patient-centered care. By consolidating multiple functionalities into a single platform, the solution enhances communication and collaboration between patients and providers, offering: – Access to appointment itineraries, telehealth visits, and secure messaging. – Completion of Smart eForms, Patient Reported Outcomes (ePROs), and surveys. – Viewing of lab results, clinical documents, and physician-validated triage symptom pathways. – Participation in Care Management programs, such as Principal Care Management (PCM). In partnership with Flatiron, Willowglade aims to simplify operational processes and technical integrations for oncology practices. By replacing up to five stand-alone systems, the combined platforms streamline business and clinical operations while enhancing the patient experience. This collaboration underscores a commitment to revolutionizing oncology care by integrating advanced digital tools to deliver seamless, effective, and patient-centric solutions